Zivo BioscienceZIVO +1.67%8 EBIT per Share is $-2.27 as of Sep. 2025. GuruFocus rates ZIVO with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 1,172 Biotechnology companies, Zivo Bioscience ranks worse than 51.11% on this metric.
Zivo Bioscience's EBIT per Share for the
three
months ended in Sep. 2025 was $-0.27.
Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 was $-2.27.
During the past 3 years, the average EBIT per Share Growth Rate was 14.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 22.40% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 11.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Zivo Bioscience's EBIT per Share or its related term are showing as below:
ZIVO'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -443.7 Med: 4.4 Max: 49
Current: 14.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Zivo Bioscience was 49.00% per year. The lowest was -443.70% per year. And the median was 4.40% per year.
ZIVO's 3-Year EBIT Growth Rate is ranked worse than 51.11% of 1172
companies
in the Biotechnology industry
Industry Median: 15.4
vs ZIVO: 14.70
Zivo Bioscience's EBIT for the
three
months ended in Sep. 2025 was $-1.02 Mil.
Zivo Bioscience (OTCPK:ZIVO) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Zivo Bioscience EBIT per Share Related Terms
Zivo Bioscience EBIT per Share Historical Data
* Premium members only.
The historical data trend for Zivo Bioscience's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.27
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zivo Bioscience (ZIVO) has a EBIT per Share of $-2.27 as of Sep. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Zivo Bioscience and its competitors. According to the industry distribution chart, Zivo Bioscience ranks #599 out of 1172 companies in the Biotechnology industry, placing it in the top 51.1%.
Is Zivo Bioscience's EBIT per Share too high?
Zivo Bioscience's current EBIT per Share is $-2.27. Based on the distribution chart, Zivo Bioscience ranks #599 out of 1172 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zivo Bioscience has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Zivo Bioscience's EBIT per Share compare to ATOS and QNCX?
According to the Biotechnology industry distribution chart, Zivo Bioscience ranks #599 out of 1172 companies for EBIT per Share. This places Zivo Bioscience in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Zivo Bioscience and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zivo Bioscience's current EBIT per Share is $-2.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zivo Bioscience stock overvalued right now?
Zivo Bioscience (ZIVO) has a current EBIT per Share of $-2.27. The current EBIT per Share is $-2.27. Zivo Bioscience's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Zivo Bioscience (ZIVO), the current EBIT per Share is $-2.27 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zivo Bioscience Inc operates in one reportable segment microalgae technology. The segment is research and development operating in both the therapeutic and nutritional sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's applications are ANIMAL APPLICATIONS, HUMAN APPLICATIONS.
8GF Score
Get the complete analysis for ZIVO
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZIVO has been successfully added to your 
